60 Degrees Pharmaceuticals (60P) is a small, pre-profitability specialty pharma company focused on infectious diseases, particularly vector-borne and parasitic diseases. Its only commercial product is Arakoda (tafenoquine), an FDA-approved once-weekly oral pill for malaria prevention in travelers. 60P licenses tafenoquine from the U.S. Army and outsources manufacturing to a contract manufacturer, paying royalties on net sales. Arakoda competes primarily against cheaper generic daily alternatives in the U.S. traveler malaria market, limiting its market penetration due to price sensitivity and formulary positioning. The more interesting near-term commercial opportunity is off-label use of Arakoda for chronic babesiosis — a tick-borne parasitic infection with no FDA-approved treatment that frequently co-occurs with Lyme disease. Physicians are already prescribing Arakoda off-label for this condition, and 60P is running clinical trials to pursue a formal babesiosis indication. If approved, 60P would hold the only FDA-approved babesiosis therapy, potentially opening a larger and less price-sensitive market. Beyond Arakoda, 60P has an early-stage pipeline including celgosivir (a glucosidase inhibitor being explored for Dengue, RSV, and COVID-19, currently paused) and an Australian Chestnut Extract dietary supplement it plans to commercialize near-term. 60P operates with just three full-time employees, funds itself through equity issuances, and partners with academic institutions to minimize R&D costs.